Marco Gerlinger Selected Research

Marco Gerlinger Research Topics

Disease

31	Neoplasms (Cancer) 11/2023 - 04/2010
10	Colorectal Neoplasms (Colorectal Cancer) 11/2023 - 02/2018
6	Renal Cell Carcinoma (Grawitz Tumor) 01/2022 - 08/2010
3	Adenocarcinoma 01/2022 - 05/2019
2	Microsatellite Instability 05/2024 - 01/2020
2	Kidney Neoplasms (Kidney Cancer) 11/2014 - 12/2013
1	Turcot syndrome 05/2024
1	Bites and Stings (Sting) 11/2021
1	Hematuria 01/2020
1	Colonic Neoplasms (Colon Cancer) 01/2020
1	Infections 01/2020
1	COVID-19 01/2020
1	Hematoma 01/2020
1	Vasovagal Syncope 01/2020
1	Sepsis (Septicemia) 01/2020
1	Pain (Aches) 01/2020
1	Thrombosis (Thrombus) 01/2020
1	Neoplasm Metastasis (Metastasis) 05/2019
1	Chromosomal Instability (Chromosome Stability) 05/2019
1	Myocardial Infarction 01/2019
1	Disease Progression 02/2018
1	Residual Neoplasm 02/2018
1	Circulating Neoplastic Cells 08/2014
1	Acidosis 06/2012
1	Follicular Lymphoma (Lymphoma, Small Cleaved Cell, Follicular) 07/2010
1	Breast Neoplasms (Breast Cancer) 04/2010
1	Triple Negative Breast Neoplasms 04/2010
1	Melanoma (Melanoma, Malignant) 12/2006

Drug/Important Bio-Agent (IBA)

10	Biomarkers (Surrogate Marker)IBA 01/2020 - 08/2010
7	DNA (Deoxyribonucleic Acid)IBA 12/2020 - 08/2013
4	Calcibiotic Root Canal SealerIBA 11/2023 - 01/2019
3	Immune Checkpoint InhibitorsIBA 05/2024 - 01/2020
3	AntigensIBA 11/2023 - 12/2013
3	Cetuximab (Erbitux)FDA Link 02/2023 - 01/2019
2	Peptides (Polypeptides)IBA 11/2023 - 12/2006
2	T-Cell Antigen Receptors (T-Cell Receptor)IBA 11/2023 - 12/2013
2	Mitogen-Activated Protein Kinase Kinases (MEKs)IBA 01/2022 - 11/2019
2	InterferonsIBA 11/2021 - 11/2019
2	AntibodiesIBA 01/2021 - 12/2020
2	Proteins (Proteins, Gene)FDA Link 01/2014 - 03/2012
1	VaccinesIBA 11/2023
1	CDX2 Transcription FactorIBA 11/2023
1	Monoclonal AntibodiesIBA 02/2023
1	Mitogen-Activated Protein KinasesIBA 01/2022
1	Docetaxel (Taxotere)FDA Link 01/2022
1	Oxaliplatin (Eloxatin)FDA LinkGeneric 01/2022
1	Leucovorin (Folinic Acid)FDA Link 01/2022
1	Fluorouracil (Carac)FDA LinkGeneric 01/2022
1	ErbB Receptors (EGF Receptor)IBA 12/2020
1	avelumabIBA 01/2020
1	Exonucleases (3' 5' Exonuclease)IBA 01/2020
1	raltitrexed (D 1694)IBA 01/2019
1	cibisatamabIBA 01/2019
1	Cell-Free Nucleic AcidsIBA 11/2018
1	Tyrosine Kinase InhibitorsIBA 11/2016
1	CarcinogensIBA 10/2014
1	Fibroblast Growth Factor 2 (Basic Fibroblast Growth Factor)IBA 12/2013
1	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 12/2013
1	Adenosine Triphosphate (ATP)IBA 06/2012
1	Small Interfering RNA (siRNA)IBA 08/2010
1	Paclitaxel (Taxol)FDA LinkGeneric 04/2010
1	Taxoids (Taxanes)IBA 04/2010
1	CeramidesIBA 04/2010
1	HLA-A*02:01 antigenIBA 12/2006
1	Differentiation AntigensIBA 12/2006

Therapy/Procedure

14	Therapeutics 11/2023 - 07/2010
8	Drug Therapy (Chemotherapy) 12/2022 - 04/2010
7	Immunotherapy 11/2023 - 12/2013
4	Precision Medicine 10/2017 - 03/2012
2	Adjuvant Chemotherapy 01/2020 - 02/2018
1	Conservative Treatment 01/2020
1	Combination Drug Therapy (Combination Chemotherapy) 04/2010
1	Neoadjuvant Therapy 04/2010